Mediation of LPS-Induced Inflammation With Pro-Resolving Treatment in Human Nasal Polyps: A Pilot Study

Abstract

Chronic rhinosinusitis (CRS) shares a common pathophysiology with other chronic inflammatory diseases, including periodic acute exacerbations and altered wound-healing processes [1]. A healthy sinonasal mucosal barrier relies on immune function to appropriately respond to airborne insults while choreographing a temporally regulated resolution of the acute physiological inflammatory response [2]. When this spatiotemporal response is disrupted, chronic inflammation may result as a potential contribution to etiopathogenesis or sustenance of inflammation in CRS. Nuclear factor-kappa B (NF-κB) signaling is one of several important contributors in the modulation of important inflammatory responses. It is recognized as an important transcription factor in the expression of various pro-inflammatory genes in chronic inflammatory diseases including CRS [3].

Lipid-derived molecules known as specialized-pro-resolving mediators (SPMs) [4] have recently been described as active components in temporal modulation of acute airway inflammatory responses and may play some role in the CRS disease process [5-7]. SPMs influence development, recruitment, and function of several inflammatory cells, including macrophages, dendritic cells, neutrophils, and lymphocytes [8].

In this study, we seek to understand SPM regulatory effects on NF-κB-associated pro-inflammatory genes using a fresh sinus tissue explant model. We hypothesize that SPM, resolvin D2 (RvD2), will mitigate lipopolysaccharide (LPS)-induced inflammation.

In the NF-κB microarray, the physiologically relevant genes with the highest fold-changes after LPS exposure were MYD88, CXCL1, and G-CSF. RvD2 treatment was also found to significantly alter expression of these genes (Figure 1). QPCR validation illustrated that G-CSF expression increased in response to LPS stimulation and was abolished with RvD2 treatment (p < 0.01; Figure 2). MYD88 and CXCL-1 were inconsistent in their expression response patterns. CXCL-1 and MYD88 exhibited no significant increase in expression at 24 h with LPS exposure compared to control, limiting experimental potential for beneficial effects of RvD2 treatment on these target genes.

CRS remains enigmatic in its pathophysiology, time course, and idiosyncratic responses to various treatments. Prior studies show that defects in the production of pro-resolving mediators, such as RvD2, have been implicated in the pathophysiology of airway disease [9]. Actions of pro-resolving mediators may offer a novel approach to treating the inflammatory processes that facilitate disease chronicity via attenuation of NF-κB effects in numerous cell types. In a PCR microarray, ex vivo polyp tissue treated with LPS for 24 h demonstrated a significant inflammatory response in G-CSF, MYD88, and CXCL1 expression, mitigated with concomitant RvD2 treatment. We attempted to validate the microarray results, and while MYD88 and CXCL1 showed an inconsistent response to LPS and RvD2, G-CSF expression pattern was convincing in its increase with LPS exposure and significant reduction with RvD2 treatment. G-CSF plays a vital role in innate immunity and inflammation by increasing the production and chemotaxis of neutrophils [10] and could be a biologically important target for SPMs in CRS.

While this pilot investigation of RvD2 effects on inflammation in CRS tissues showed some interesting findings, further work is required. The small study size (n = 3) could be expanded to include subjects with more neutrophilic or mixed inflammatory disease, such as nonpolyp CRS or select CRSwNP cases. More cellular and molecular targets could be included, along with specific assessment of NF-κB activity. The inflammatory response is dependent on temporal regulation, and additional exposure time courses to pro-inflammatory stimuli, RvD2, and other SPMs could be tested. Lastly, we utilized a novel ex vivo tissue culture approach to include the numerous cell types involved in CRS, and further work is required to understand nuances of this experimental model, including a detailed understanding of the ex vivo maintenance and function of the various cell populations.

This study establishes a potential effect of the specialized pro-resolving mediator, RvD2, in a CRS polyp tissue explant model. SPMs may elicit changes in gene expression that resolve active inflammation, including gene products that influence immune cell development and recruitment, and cytokines that direct acute phase responses.

VRR has served as a consultant for Medtronic, Inc., and 3D-Matrix, which are unaffiliated with the current study.